The Europe autoimmune disease diagnostics market is expected to register a CAGR of 7.8%, during the forecast period, 2018 to 2023. Autoimmune diseases are a group of diseases characterized by inflammatory reactions caused by immune responses mistakenly generated against body tissues. The term autoimmune disease refers to a varied group of illnesses that involve almost every human organ system. Environmental, infectious, and genetic factors play an important role in initiating or exacerbating autoimmune diseases.
Treatment of autoimmune diseases requires diagnosis of the disease at the onset of disease or later. This involves clinical laboratories checking for symptoms and providing the information to physician for better treatment of the disease. All the diagnostic laboratories do not have proper equipment for carrying out immunoassays. In that case, patient will face trouble in getting the tests done and then handing over the result to the physician. To overcome these problems, recently physicians and clinical laboratories started collaborating. Since, a physician knows where proper immunoassays and immunodiagnostics can be carried out, physician collaborates with that laboratory and suggests patient to get their tests done from there and the results will directly be sent to the physician. And, with increasing usage of Electronic Medical Records (EMR), labs have access to real-time test data and metrics extracted from the Laboratory Information System (LIS) and physicians too have access to these records, which increases efficiency in diagnosis, thus boosting autoimmune diagnostics market. The other factors, such as improved laboratory automation, growing public awareness of autoimmune disease, technological advancements, and expansion in coverage allowed by patient protection and affordable care act are driving the Europe autoimmune disease diagnostics market.
Diagnosis of autoimmune diseases is a time consuming process. It involves procedures such as serum testing for diseases like rheumatoid arthritis, Addison’s disease, Hashimoto’s disease, and others. Testing protocols allow autoimmune disorders to be diagnosed in a highly efficient, cost effective manner. However, turnaround time for the test results is slow, owing to lesser automation techniques. It takes days to deliver all test results to the patients with proper explanation of false positive results. For example, autoimmune Lymph proliferative Syndrome is an autoimmune disease with turnaround time of up to 12 weeks; single gene sequencing takes 4 weeks. Therefore, this slow turnaround time is hindering the Europe autoimmune disease diagnostics market. The other factor, such as high frequency of false positive result is also hindering the growth of the market.
The Germany autoimmune disease diagnostics market holds the largest market share in 2017 in Europe region with a CAGR of over 7% due to the increasing healthcare expenditure and increasing prevalence of autoimmune diseases in this region.
The major players include - F. Hoffmann-la Roche, Siemens Healthineers Inc, Biomérieux, Novartis AG, Thermo Fisher Scientific, Myriad Genetics, Abbott Laboratories and Bio-rad Laboratories, among others.
Looking to Customize Report?